Status:
TERMINATED
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
Lead Sponsor:
Profil Institut für Stoffwechselforschung GmbH
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medication...
Eligibility Criteria
Inclusion
- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- Male or female aged 18-65 years (both inclusive)
- T2DM diagnosis
Exclusion
- Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics
- Use of GLP-1 mimetics or DPP-IV inhibitors
- Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%
Key Trial Info
Start Date :
July 16 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 23 2018
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT02231658
Start Date
July 16 2015
End Date
July 23 2018
Last Update
October 17 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Josef-Hospital, Universitätsklinik
Bochum, Germany, 44791
2
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany, 41460